Microbiome dysbiosis and chemotherapy resistance in acute myeloid leukemia (AML)
AML often relapses due to chemotherapy resistance, increasingly linked to gut microbiome dysbiosis. Microbial drug modification, immune modulation, and metabolite-driven survival/epigenetic changes (e.g., SCFAs, kynurenine) promote resistance. Clinical data associate reduced diversity, loss of Faecalibacterium, and Enterococcus overgrowth with poorer outcomes. Microbiome interventions (FMT, probiotics, diet) show promise; priorities are standardizing methods and defining microbe-metabolite mechanisms to guide trials.
Authors
- Farzaneh Tavakoli (ORCID: https://orcid.org/0000-0002-5898-591X)
- Maojin Tian
- Amirhossein Zeynalabadi
- Seyed Shahabedin Alemohammad
- Hamed Soleimani Samarkhazan
- Ali Shams
- Milad Fakhraei Manesh
Institutions
- Iran University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Shahid Sadoughi University of Medical Sciences and Health Services (IR)
- High Institute for Education and Research in Transfusion Medicine (IR)
- Central Hospital of Zibo (CN)
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- npj Biofilms and Microbiomes
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1038/s41522-025-00891-8
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00